-
March 26, 2020
-
August 2018
Recent News
AGT-181 Update
Key opinion leaders provide their perspectives on recently presented AGT-181 data, what these data mean for Hurler patients and the implications of these data on other lysosomal storage diseases and central nervous system disorders.
Our Technology
ArmaGen's proprietary technology platform takes advantage of the body's natural system to non-invasively deliver therapeutics to the brain
Learn More
ArmaGen: Transporting Therapies Across the Blood‑Brain Barrier
ArmaGen’s proprietary platform technology fuses a therapeutic to an antibody that binds to the specific receptors that deliver insulin, transferrin, or LRP1 (or any future receptor not yet identified) tothe brain, enabling the fusion protein to travel through the BBB in a process known as receptor-mediated transcytosis. ArmaGen’s platform is unique as it targets multiple antibody-based receptor-mediated transporters.
ArmaGen: Transporting Therapies Across the Blood‑Brain Barrier

Following transcytosis, the therapeutic may act in several different ways:
- Binding with soluble ligands (molecules that bind to receptors) such as inflammatory proteins
- Transmitting a secondary message through binding to an additional receptor (such as glial cell-derived neurotrophic factor [GDNF] or erythropoietin [EPO]) on the surface of the cell membrane
- Binding to insulin receptors on the surface of the cell membrane to deliver its payload within the neuron, as a means to treat lysosomal storage diseases such as Hunter and Hurler syndromes
- Preventing expression of a gene through delivery of therapeutics such as siRNA into the nucleus of the neuron
The blood‑brain barrier (BBB) is an exclusive entryway that protects the brain from blood-borne gate‑crashers like bacteria. In doing so, it also prevents the uptake of all large-molecule drugs and nearly all small-molecule drugs. ArmaGen aims to transform the treatment of severe neurological disorders by using the body’s natural systems to deliver therapeutics across the BBB.
Solving the Blood‑Brain Barrier Dilemma
During a decade-long scientific journey, ArmaGen scientists published extensively in respected peer‑reviewed journals.
Fusion antibody for Alzheimer’s disease with bi-directional transport across the blood-brain barrier transport and Abeta fibril disaggregation
Boado, et al
Bioconjugate Chemistry
Feb 2007
Fusion antibody for Alzheimer’s disease with bi-directional transport across the blood-brain barrier transport and Abeta fibril disaggregation
Boado, et al

For more details, click here.
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier
Boado, et al
Biotechnology and Bioengineering
Feb 2008
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier
Boado, et al

For more details, click here.
Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery
Pardridge and Boado
Pharmaceutical Research
Jul 2009
Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery
Pardridge and Boado

For more details, click here.
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein
Boado, et al
Biotechnology Journal
Jan 2010
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein
Boado, et al

For more details, click here.
Chronic dosing of mice with a transferrin receptor monoclonal antibody-GDNF fusion protein
Zhou, et al
Drug Metabolism & Disposition
Apr 2011
Chronic dosing of mice with a transferrin receptor monoclonal antibody-GDNF fusion protein
Zhou, et al

For more details, click here.
Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein
Boado, et al
Molecular Pharmaceutics
Jun 2011
Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein
Boado, et al

For more details, click here.
Re-engineering biopharmaceuticals for targeted delivery across the blood-brain barrier
Pardridge and Boado
Methods in Enzymology
2012
Re-engineering biopharmaceuticals for targeted delivery across the blood-brain barrier
Pardridge and Boado

For more details, click here.
Blood-brain barrier molecular Trojan horse enables brain imaging of radioiodinated recombinant protein in the Rhesus monkey
Boado, et al
Bioconjugate Chemistry
Oct 2013
Blood-brain barrier molecular Trojan horse enables brain imaging of radioiodinated recombinant protein in the Rhesus monkey
Boado, et al

For more details, click here.
Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys
Boado, et al
Biotechnology and Bioengineering
Aug 2014
Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys
Boado, et al

For more details, click here.
Our Mission
ArmaGen aims to transform the treatment of severe neurological disorders by engineering and developing revolutionary therapies for the brain.
We are passionate about science and driven by the opportunity to make a difference in the lives of patients. Our people work with speed and skill to advance innovative therapies both in partnership with collaborators and as an emerging leader in the fight against central nervous system disorders.